31 October 2022
News
Small Pharma Receives Approval For First-In-Human Phase I Clinical Trial With SPL028
Aims to assess the safety & tolerability of IM and IV administration of SPL028.
19 September 2022
News
Small Pharma Completes Enrollment In Phase IIa DMT-Assisted Psychotherapy Clinical Trial In Patients With Major Depressive Disorder
Dosing for primary endpoint now complete.
15 August 2022
News
Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study
Study will explore the interaction between SSRI antidepressants and SPL026.
20 April 2022
Insights
A brief history of DMT
A brief history on this a naturally-occurring, fast-acting psychoactive molecule.
22 March 2022
Events & Conferences
Small Pharma CEO Peter Rand & CMSO Dr Carol Routledge at the 34th Annual Roth Conference
Small Pharma to present at the 34th Annual Roth Conference in March.
10 March 2022
News
Small Pharma Expands Potential of Commercial Portfolio with DMT-based Psychedelic Assets
Small Pharma expands its commercial portfolio with progress of two new trials.
22 February 2022
News
World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
Small Pharma reports Phase Ia clinical trial results.
15 November 2021
News
Discussions With FDA Provide Guidance For Phase IIb Clinical Trial Design For DMT-assisted Therapy For Major Depressive Disorder
Discussions with FDA provide guidance for Phase IIb clinical trial design.
19 October 2021
News
First patient dosed in Phase IIA DMT-assisted therapy clinical trial
First patient dosed in Phase IIa study of SPL026 in combination with supportive therapy.
1 June 2021
News
Small Pharma Inc. expands Phase I/IIa clinical trial with additional study site
Appointment of MAC Clinical Research to accelerate timeline of Phase I/IIa clinical trial of SPL026…